Renalytix Plc (RENX.L)
| Previous close | 23.50 |
| Open | 23.00 |
| Bid | 23.00 x 0 |
| Ask | 24.00 x 0 |
| Day's range | 23.00 - 23.10 |
| 52-week range | 10.00 - 150.00 |
| Volume | |
| Avg. volume | 587,961 |
| Market cap | 34.067M |
| Beta (5Y monthly) | 1.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings date | 15 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.39 |
Globe NewswireRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
LONDON and NEW YORK, May 15, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal third quarter ended March 31, 2024. The Company made continued progress towards commercial adoption with inclusion of KidneyIntelX in clinical guidelines, issuance of
- Globe Newswire
Renalytix to Report Financial Results for Third Quarter Fiscal Year 2024 on May 15
LONDON and SALT LAKE CITY, May 09, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its third quarter fiscal year 2024 financial results on Wednesday, May 15, 2024 before U.S. market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST) on the day. Conference
- PR Newswire
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
Pentwater Capital Management LP - Form 8.3 - Renalytix PLC
